As previously reported, the 2018 Federal Budget announced the creation of an Advisory Council on the Implementation of National Pharmacare. On March 6, 2019, the Advisory Council delivered an interim report, with three initial recommendations:
- Creating a national drug agency to oversee national pharmacare;
- Developing a comprehensive, evidence-based list of prescribed drugs - a national formulary - to harmonize coverage across Canada; and
- Investing in data on prescription drugs and information technology systems.
The Advisory Council indicated that the final report should be issued in the coming months.
On March 19, 2019, the Federal government delivered the 2019 Federal Budget, which reflects these recommendations. In particular, the government plans to create a new Canadian Drug Agency, a national formulary, and a national strategy for high-cost drugs for rare diseases "to help Canadians get better access to the effective treatments they need.... an important first step in expanding drug coverage through federal support." While the mandate for the Canadian Drug Agency is still in development, it will "be able to provide impartial and independent advice so that drug evaluation and price negotiation could be carried out by a single, coordinated entity."
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
